Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PLx Pharma Inc. to Present at JMP Securities 2022 Life Sciences Conference on June 15, 2022
Details : VAZALORE is an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses. VAZALORE delivers aspirin differently from plain and enteric coated aspirin products.
Product Name : Vazalore
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 06, 2022
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PLx Pharma Inc. to Present at Oppenheimer & Co’s 32nd Annual Healthcare Conference on March 15, 2022
Details : VAZALORE is an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses. VAZALORE delivers aspirin differently from plain and enteric coated aspirin products, delivers fast, reliable absorption for pain relief plus the lifesaving b...
Product Name : Vazalore
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 03, 2022
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PLx Pharma Inc. Provides VAZALORE Launch Update
Details : VAZALORE delivers aspirin differently from plain and enteric coated aspirin products. VAZALORE delivers fast, reliable absorption for pain relief plus the lifesaving benefits of aspirin.
Product Name : Vazalore
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 29, 2021
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VAZALORE delivers aspirin differently from plain and enteric coated aspirin products. The special complex inside the capsule allows for targeted release of aspirin, limiting its direct contact with the stomach.
Product Name : Vazalore
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 14, 2021
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PLx Pharma Inc.’s VAZALORE™ Now on Shelves; National Media Campaign Launches Today
Details : VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast platelet inhibition as compared to enteric-co...
Product Name : Vazalore
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 26, 2021
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PLx Pharma Receives FDA Approval of SNDAs for Both VAZALORE 325 mg and 81 mg
Details : VAZALORE is the first ever liquid-filled aspirin capsule with an innovative delivery platform indicated as a pain reliever, fever reducer and for aspirin therapy in vascular indications.
Product Name : Vazalore
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 03, 2021
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The 325 mg sNDA provided information on a change in formulation and a new manufacturing site for the currently approved VAZALORE and a bioequivalence study data from a recently completed BE study. The submission for 81 mg dose provided for a new product ...
Product Name : Vazalore
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 16, 2020
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Park West Asset Management
Deal Size : $8.0 million
Deal Type : Financing
PLx Pharma Inc. Announces Completion of $8 Million Convertible Preferred Stock Financing
Details : This financing round will fund PLx Pharma's lead candidate, VAZALORE, through the final steps of the regulatory process.
Product Name : Vazalore
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 18, 2020
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Park West Asset Management
Deal Size : $8.0 million
Deal Type : Financing